A Phase 3b, Open-label, Multicenter Study to Evaluate Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504040-34-01

Acronym

CNTO1959CRD3008

Enrollment

151

Registered

2024-10-29

Start date

2024-11-12

Completion date

Unknown

Last updated

2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn’s Disease

Brief summary

Proportion of participants achieving a Magnetic Resonance Index of Activity (MaRIA) <11 in all intestinal segments, at Week 48.

Interventions

DRUGGuselkumab- Solution for infusion- 10 mg/ml

DRUGGuselkumab

DRUGGuselkumab - solution for injection in pre-filled syringe - 100 mg/mL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving a Magnetic Resonance Index of Activity (MaRIA) <11 in all intestinal segments, at Week 48.	—

Countries

Belgium, Czechia, France, Germany, Italy, Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026